A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

被引：11

作者：

Sangro, Bruno ^{[1
,2
]}

Harding, James J. ^{[3
]}

Johnson, Matthew ^{[4
]}

Palmer, Daniel H. ^{[5
,6
]}

Edeline, Julien ^{[7
]}

Abou-Alfa, Ghassan K. ^{[8
]}

Cheng, Ann-Lii ^{[9
]}

Decaens, Thomas ^{[10
]}

El-Khoueiry, Anthony B. ^{[11
]}

Finn, Richard S. ^{[12
]}

Galle, Peter R. ^{[13
]}

Park, Joong-Won ^{[14
]}

Yau, Thomas ^{[15
]}

Begic, Damir ^{[16
]}

Shen, Yun ^{[16
]}

Neely, Jaclyn ^{[16
]}

Sama, Ashwin Reddy ^{[16
]}

Kudo, Masatoshi ^{[17
]}

机构：

[1] Clin Univ Navarra, Pamplona, Spain

[2] CIBEREHD, Pamplona, Spain

[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[4] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA

[5] Univ Liverpool, Liverpool Expt Canc Med Ctr, Liverpool, Merseyside, England

[6] Clatterbridge Canc Ctr, Liverpool, Merseyside, England

[7] Ctr Eugene Marquis, Rennes, France

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Univ Grenoble Alpes, Dept Gastroenterol & Hepatol, INSERM, Grenoble, France

[11] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[12] UCLA, Geffen Sch Med, Los Angeles, CA USA

[13] Univ Med Ctr Mainz, Mainz, Germany

[14] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea

[15] Univ Hong Kong, Hong Kong, Peoples R China

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Kindai Univ, Fac Med, Osaka, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.TPS349

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS349

引用

页数：2

共 50 条

[41] Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
Long, Georgina V.
Atkinson, Victoria
Lo, Serigne
Guminski, Alexander David
Sandhu, Shahneen Kaur
Brown, Michael Paul
Gonzalez, Maria
Scolyer, Richard A.
Emmett, Louise
McArthur, Grant A.
Menzies, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Zimmer, Lisa
Livingstone, Elisabeth
Hassel, Jessica C.
Fluck, Michael
Eigentler, Thomas
Loquai, Carmen
Haferkamp, Sebastian
Gutzmer, Ralf
Meier, Friedegund
Mohr, Peter
Hauschild, Axel
Schilling, Bastian
Menzer, Christian
Kieker, Felix
Dippel, Edgar
Roesch, Alexander
Simon, Jan-Christoph
Conrad, Beate
Koerner, Silvia
Windemuth-Kieselbach, Christine
Schwarz, Leonora
Garbe, Claus
Becker, Juergen C.
Schadendorf, Dirk
LANCET, 2020, 395 (10236): : 1558 - 1568
[43] CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.
Moehler, Markus H.
Janjigian, Yelena Yuriy
Adenis, Antoine
Aucoin, Jean-Sebastien
Boku, Narikazu
Chau, Ian
Cleary, James M.
Feeney, Kynan
Franke, Fabio A.
Mendez, Guillermo Ariel
Schenker, Michael
Li, Mingshun
Hitre, Erika
Couture, Felix
Karamouzis, Michalis
Etienne, Pierre-Luc
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[44] Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies
Nadal, R.
Mortazavi, A.
Stein, M.
Pal, S. K.
Davarpanah, N.
Parnes, H. L.
Ning, Y. M.
Cordes, L. M.
Lin, J.
Bagheri, M.
Linderberg, L.
Berniger, M.
Steinberg, S. M.
Moore, T.
Lancaster, T.
Aviles, M.
Costello, R.
Bottaro, D. P.
Dahut, W. L.
Apolo, A. B.
ANNALS OF ONCOLOGY, 2017, 28
[45] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
Yau, T.
Cheng, A-L.
Meyer, T.
Ryoo, B-Y.
Park, J-W.
Klumpen, H-J.
Lim, H. Y.
Kim, S.
Knox, J.
Patel, M.
El-Khoueiry, A. B.
Kelley, R. K.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2018, 29
[46] Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.
Kudo, Masatoshi
Ueshima, Kazuomi
Ikeda, Masafumi
Torimura, Takuji
Tanabe, Nobukazu
Aikata, Hiroshi
Izumi, Namiki
Yamasaki, Takahiro
Nojiri, Shunsuke
Hino, Keisuke
Tsumura, Hidetaka
Kuzuya, Teiji
Isoda, Norio
Yasui, Kohichiroh
Yoshimura, Kenichi
Okusaka, Takuji
Furuse, Junji
Kokudo, Norihiro
Okita, Kiwamu
Arai, Yasuaki
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[47] CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
Gettinger, S.
Beck, T.
Yang, X.
Telivala, B.
Morgensztern, D.
Velcheti, V.
Ramalingam, S. S.
Schalper, K.
Dajee, M.
Ranck, A.
Yang, R.
Spigel, D. R.
ANNALS OF ONCOLOGY, 2018, 29
[48] CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.
Kelly, Ronan Joseph
Lockhart, Albert C.
Jonker, Derek J.
Melichar, Bohuslav
Andre, Thierry
Chau, Ian
Clarke, Stephen John
Cleary, James M.
Doki, Yuichiro
Franke, Fabio Andre
Kitagawa, Yuko
Mariette, Christophe
Montenegro, Paola Catherine
Roca, Enrique Luis
Ciprotti, Marika
Moehler, Markus
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[49] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Zhu, Andrew X.
Rosmorduc, Olivier
Evans, T. R. Jeffry
Ross, Paul J.
Santoro, Armando
Carrilho, Flair Jose
Bruix, Jordi
Qin, Shukui
Thuluvath, Paul J.
Llovet, Josep M.
Leberre, Marie-Aude
Jensen, Markus
Meinhardt, Gerold
Kang, Yoon-Koo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566
[50] CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.
Kelly, Ronan Joseph
Lockhart, Albert C.
Jonker, Derek J.
Melichar, Bohuslav
Andre, Thierry
Chau, Ian
Clarke, Stephen John
Cleary, James M.
Doki, Yuichiro
Franke, Fabio A.
Kitagawa, Yuko
Marlette, Christophe
Montenegro, Paola Catherine
Mendez, Guillermo Ariel
Ciprotti, Marika
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →